Advances in biotechnology and spreading of biological therapies during the last three decades resulted in the approval of several new and effective disease modifying treatment options in rheumatoid arthritis.The most effective current treatment of rheumatoid arthritis varies from patient to patient, and a common theme among them is the combined use of a conventional systemic disease modifying agent (csDMARD) plus either a biological (bDMARD) or a targeted systemic (tsDMARD) drug. It is crucial for any physician who deals with rheumatoid arthritis patients to be up to date on the latest information that influences the guidelines of their treatments. There is currently an ever-emerging front for inflammatory and immune modulation therapies. Staying up to date on both the benefits and drawbacks of new therapies will lead to improved patient outcomes in the coming years.